Longer colonic transit time is associated with laxative and drug use, lifestyle factors, and symptoms of constipation

Johan Bohlin1,*, Erik Dahlin1,*, Julia Dreja2, Bodil Roth1, Olle Ekberg2 and Bodil Ohlsson1

Abstract

Background: Gastrointestinal symptoms and changes in colonic transit time (CTT) are common in the population.

Purpose: To evaluate consecutive patients who had been examined for CTT, along with completion of a diary about laxative and drug use, lifestyle factors, and gastrointestinal symptoms, to identify possible associations with longer or prolonged CTT.

Material and Methods: A total of 610 consecutive patients had undergone the radiopaque marker method with an abdominal X-ray for clinical purposes. The patients had completed a diary regarding medical treatment, lifestyle factors, stool habits, and their perceived constipation and abdominal pain during the examination period. The associations between CTT and laxative use, lifestyle factors, stool habits, and symptoms were calculated by logistic regression.

Results: Women had longer CTT (2.5 [1.6–3.9] vs. 1.7 [1.1–3.0] days, \(P < 0.001\)), lower weekly stool frequency (6 [3–10] vs. 8 [5–12], \(P = 0.001\)), and perceived more constipation (\(P = 0.025\)) and abdominal pain (\(P = 0.001\)) than men. High coffee consumption (\(P = 0.045\)), bulk-forming (\(P = 0.007\)) and osmotic (\(P = 0.001\)) laxatives, and lower stool frequency, shaped stool, and perceived constipation (\(P\) for trend < 0.001) were associated with longer CTT. In total, 382 patients (63%) were treated with drugs affecting motility. In the 228 patients without drug treatment, longer CTT was associated with female sex and smoking, and lower frequency of symptoms and prolonged CTT were observed compared to patients using drugs. Tea, alcohol, and abdominal pain did not associate with CTT.

Conclusions: Female sex, coffee, smoking, drug use, infrequent stools, shaped stool, and perception of constipation are associated with longer or prolonged CTT.

Keywords
Colonic transit time, constipation, functional gastrointestinal disorders (FGID), laxatives, lifestyle factors

Introduction

Functional gastrointestinal disorders (FGID)—e.g. irritable bowel syndrome (IBS)—are characterized by abdominal pain and dysmotility, without obvious structural changes (1). Inflammatory bowel disease (IBD) may exhibit abdominal pain and dysmotility in the absence of clinical overt inflammatory relapse of the disease (2). Apart from primary gastrointestinal (GI) diseases, patients with diabetes mellitus, multiple sclerosis, and Parkinson’s disease may also suffer from GI symptoms and dysmotility (3–5).

Colonic transit time (CTT), also called GI transit time, oroanal transit time (OATT), or whole gut transit time (WGTT), is the total amount of time for food to pass through the GI system (6,7). Pathological transit time can either be prolonged or shortened, depending on the type and character of the disease manifested. The underlying etiology and pathophysiology affecting transit time are mostly unclear.

1Lund University, Skane University Hospital, Department of Internal Medicine, Malmö, Sweden
2Lund University, Skane University Hospital, Department of Imaging and Function, Lund University, Skåne University Hospital, Malmö, Sweden
*Equal contributors.

Corresponding author:
Bodil Ohlsson, Department of Clinical Sciences, Skåne University Hospital, Jan Waldenström gata 15, floor 5, S-205 02 Malmö, Sweden.
Email: Bodil.ohlsson@med.lu.se

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
There is no “gold standard” of examining GI motility although a host of new promising methods are emerging, utilizing techniques such as magnetic resonance imaging (MRI), high-resolution manometry, and three-dimensional (3D) Transit system (8). A plain abdominal X-ray together with ingestion of radiopaque markers (ROM) is one method widely used in both clinical and research settings, to calculate the CTT, depending on how many markers that remain in the colon (6,7). No review is available to reflect or evaluate the results of the ROM method and its utilization in the clinical setting.

Our hypotheses were that lifestyle factors affect CTT and that longer CTT may affect or induce GI symptoms. To address these two hypotheses, we summarized the results from consecutive patients who had been examined by the ROM method to assess CTT and had completed a daily questionnaire during the study period about drug treatment; coffee, tea, smoking, and alcohol habits; and symptoms of constipation and abdominal pain. The primary aim of this study was to identify possible factors and symptoms which associated with longer or prolonged CTT. The secondary aim was to compile all ROM examinations to evaluate the information given.

Material and Methods

Patients

The participants consisted of 638 consecutive patients who had been examined by the ROM method over 17 years at the Department of Imaging and Function. All patients had received a clinical referral for examination of CTT and were handled according to the same clinical routines, independent of disease. Twenty-seven participants were excluded due to missing information of CTT and one was excluded due to being five years old, leaving 610 participants in the final study cohort.

This retrospective study was approved by the regional ethics committee of Lund/Malmö (2017/151, date of approval 20170314) and performed in accordance with the declaration of Helsinki. All participants were given the opportunity to withdraw inclusion via Lund University Population Research Platform webpage (9).

Measurement of colonic transit time

Ten radiopaque rings were ingested at the same time every morning for six days. On the sixth day, 20 radiopaque rods were ingested in addition. On the seventh day, a plain abdominal X-ray in anteroposterior or posteroanterior projection was obtained that covered the whole abdomen. To calculate CTT, the number of radiopaque rings remaining in the intestine were counted and divided by 10 (10). The definition of a pathologically prolonged CTT was set to >2.2 days in men and >4.2 days in women, according to established criteria (6,7). All participants were instructed to refrain from using any laxatives during the days under surveillance.

Study questionnaire

Each participant was instructed to complete a questionnaire each day regarding their daily consumption of coffee, tea, alcohol, cigarettes, laxatives, and other medications during the examination period. Type of alcoholic beverages was noted. The questionnaire included questions about number of stools, stool consistency, and perceived constipation and abdominal pain on a scale in the range of 0–3.

Data categorization

Continuous variables were not normally distributed, why all data were categorized. Values of CTT were divided into quartiles. Patient age was divided into five age groups: <30, 30–39, 40–49, 50–59 and ≥60 years. Coffee and tea intake was reported in number of cups each day; the total numbers of cups were then summarized for the six-day period. Likewise, alcohol intake was reported in number of standard drinks each day and was then summarized for the six-day period. Henceforth, the six-day period will be referred to as a week for simplicity. Coffee (cups/week), tea (cups/week), and alcohol (standard drinks/week) intakes were grouped into tertiles, because of uneven groups when using quartile grouping. Smoking was categorized as smoker or non-smoker.

Stool consistency was assigned to one of three groups: watery stool; shaped stool; or mixed stool, which means the appearance of both watery and shaped stool on the same day. Both abdominal pain and constipation were rated on a scale of 0–3 for each day; 0 being “no abdominal pain” or “no constipation,” respectively, and 3 being “severe pain” or “severe constipation,” respectively. The individual days were then summarized to a total number in the range of 0–18. Laxatives were divided into four categories based on their main mode of action: bulk-forming agents; osmotic agents; stool softener agents; and stimulant agents. If a patient used laxatives from more than one category, the patient was assigned to the laxative considered most potent, according to the following grading based on the standard therapy progression (11): stimulant agents > stool softener agents > osmotic agents > bulk-forming agents.
**Data analysis**

IBM SPSS statistics version 24.0 (SPSS Inc., Chicago, IL, USA) was used for all statistical analyses.

Differences between men and women and between patients with or without medical treatment were assessed using Mann–Whitney U test for ordinal values and Fisher’s exact test for nominal values. CTT values were split by the median value to longer and shorter CTT. Factors intended to study for influence on CTT (independent variables), namely, gender, age, smoking, amount of coffee, tea and alcohol intake, type of alcohol intake, and type of laxatives were examined using an unconditional logistic regression to calculate crude odds ratio (OR) and 95% confidence interval (CI). Analyses were then performed adjusted for all variables. A second grouping was made based on pathological and normal CTT (>2.2 days for men and > 4.2 days for women) (6,7). After unconditional logistic regression to calculate crude OR and 95% CI, analyses were adjusted for all variables statistically significant in the unconditional calculation. To study the associations between CTT and GI symptoms (dependent variables), the number of stools and perception of constipation and abdominal pain were divided by the median value into two groups, and unconditional logistic regression to calculate crude OR and 95% CI were performed, followed by adjustment for gender, coffee intake, and laxative use, since these factors were associated with longer CTT and thus considered potential confounders. Stool consistency was divided into watery and shaped stool, excluding participants with mixed stool consistency, and calculated in the same way as stool frequency and GI symptoms. A subgroup analysis was performed according to sex and smoking, since these factors were associated with longer CTT in the subgroup. Furthermore, an interaction analysis was performed between sex and each factor in the adjusted models by including an interaction term. The adjusted analyses were performed as a complete case-analysis. A P value <0.05 was considered statistically significant.

**Results**

**Patient characteristics**

The final sample consisted of 610 patients, 129 (21%) men and 481 (79%) women. No statistically significant differences in age, smoking prevalence, or in the consumption of cigarettes, coffee, tea, alcohol, or laxatives were found between men and women. Men drank more beer and women drank more wine (Table 1). When comparing CTT, men showed a faster transit time of 1.7 days (interquartile range = 1.1–3.0 days) compared to women with 2.5 days (interquartile range = 1.6–3.9 days) (P<0.001). In accordance with this, the number of stools per week was found to be higher for men than for women (P = 0.001), but with no differences in stool form between sexes. Both abdominal pain (P = 0.001) and constipation (P = 0.025) were found to be rated lower in men than in women (Table 1).

Except laxative use, the most common self-reported medications were analgesic drugs in the form of paracetamol or non-steroidal anti-inflammatory drugs (NSAIDs) (n = 61, 10%), proton pump inhibitors or histamine antagonists (n = 60, 10%), antidepressants (n = 41, 7%), sedatives and/or sleeping pills (n = 37, 6%), beta blockers (n = 27, 4%), other hypertensive drugs (n = 20, 3%), motility-stimulating drugs (n = 20, 3%), opioid or opioid-like drugs (n = 22, 3%), and antispasmodic drugs (n = 17, 3%). Altogether, 317 patients (52%) used any of these drugs during the week. Only 228 out of 610 patients (37%) were without treatment of both laxatives and other motility-modulating medications during the examination period.

**Laxatives and lifestyle factors in association with colonic transit time**

Longer CTT was associated with female sex, higher coffee consumption and intake of bulk-forming and osmotic laxatives, and tended to be associated with smoking (Table 2). No sex interactions were found in laxative use or lifestyle factors (data not shown). In men, prolonged CTT was associated with high coffee consumption (P = 0.01) and use of bulk-forming laxatives (P = 0.007), with a tendency of association in the age range of 30–49 years compared to age <30 years (Table 3). In women, prolonged CTT did not associate with any lifestyle factor, but was associated with use of osmotic (P = 0.005) and stimulant laxatives (P = 0.019) (Table 3).

**Gastrointestinal symptoms in association with colonic transit time**

A more frequent stool passing (median value ≤6) was inversely associated with CTT [OR = 0.08; 95% CI = 0.04–0.14, highest vs. lowest quartile, P for trend <0.001]. In analogy, shaped stool (OR = 6.75; 95% CI = 2.42–18.84, highest vs. lowest quartile, P for trend <0.001) and aggravated perception (median value ≤2) of constipation (OR = 5.44; 95% CI = 3.15–9.39, highest vs. lowest quartile, P for trend <0.001) were associated with longer CTT. The abdominal pain did not associate with CTT (data not
shown). No sex interactions were found in the associations between CTT and GI symptoms (data not shown).

**Associations in patients with or without any drug treatment**

When excluding all patients with any ongoing medication that could affect gut motility, female sex (OR = 3.90; 95% CI = 1.96–7.75; \( P < 0.001 \)) and smoking (OR = 1.98; 95% CI = 1.02–3.84; \( P = 0.04 \)) were associated with longer CTT, whereas coffee intake did not associate with CTT (OR = 1.75; 95% CI = 0.78–3.94; highest vs. lowest tertiles, \( P = 0.18 \)). More infrequent stool passing, shaped stool form, and perceived constipation were associated with longer CTT, whereas abdominal pain did not associate with CTT (Table 4). Patients without ongoing medication had less perception of constipation (0 [0–7] vs. 4 [0–10], \( P < 0.001 \)), abdominal pain (4 [0–9] vs. 6 [2–10],

---

**Table 1.** Patient characteristics.

|                         | Men (n = 129)       | Women (n = 481)      | \( P \) value |
|-------------------------|---------------------|----------------------|--------------|
| Age (years)             | 44 (31–58)          | 42 (30–56)           | 0.435        |
| Smoking (n, %)          | 40 (31)             | 167 (35)             | 0.465        |
| Cigarettes (n/week)     | 0 (0–12)            | 0 (0–29)             | 0.289        |
| Coffee (cups/week)      | 8 (0–16)            | 10 (0–18)            | 0.114        |
| Tea (cups/week)         | 1 (0–6)             | 1 (0–6)              | 0.940        |
| Alcohol (std/week)      | 0 (0–3)             | 0 (0–3)              | 0.676        |
| Alcohol type (n, %)     |                     |                      |              |
| No alcohol              | 73 (57)             | 243 (50)             | 0.006        |
| Spirits                 | 6 (5)               | 21 (4)               |              |
| Wine                    | 28 (22)             | 170 (35)             |              |
| Beer                    | 19 (15)             | 37 (8)               |              |
| Missing                 | 3 (2)               | 10 (2)               |              |
| CTT (days)              | 1.7 (1.1–3.0)       | 2.5 (1.6–3.9)        | \(< 0.001\)  |
| CTT > 2.2 days (n, %)   | 50 (39)             | 271 (56)             | \(< 0.001\)  |
| CTT > 4.2 days (n, %)   | 14 (11)             | 105 (22)             | 0.006        |
| Abdominal pain* (0–18)  | 3 (0–8)             | 6 (2–10)             | 0.001        |
| Missing                 | 1                   | 1                    |              |
| Constipation* (0–18)    | 0.5 (0–7)           | 3 (0–9)              | 0.025        |
| Missing                 | 0                   | 3                    |              |
| Stools/week             | 8 (5–12)            | 6 (3–10)             | 0.001        |
| Missing                 | 2                   | 2                    |              |
| Stool consistency       |                     |                      |              |
| Zero stool              | 3 (2)               | 19 (4)               | 0.188        |
| Watery stool            | 12 (9)              | 36 (8)               |              |
| Shaped stool            | 44 (34)             | 195 (40)             |              |
| Mixed stool             | 64 (50)             | 210 (44)             |              |
| Missing                 | 5 (4)               | 21 (4)               |              |
| Laxative (n, %)         |                     |                      |              |
| No laxative             | 95 (74)             | 353 (73)             | 0.898        |
| Bulk-forming            | 15 (12)             | 61 (12)              |              |
| Osmotic                 | 7 (5)               | 26 (5)               |              |
| Stool softener          | 5 (4)               | 15 (3)               |              |
| Stimulant               | 5 (5)               | 20 (4)               |              |
| Missing                 | 2                   | 6                    |              |

Values are presented as median (interquartile range [IQR]) or n (%). Statistical calculations were performed using the Mann–Whitney U test for ordinal values and Fisher’s exact test for nominal values. \( P < 0.05 \) is considered statistically significant.

*Rated on a scale of 0–3 for each day and summarized to a total number ranging from 0–18.

CTT, colonic transit time.
Table 2. Associations of shorter and longer colonic transit time.

|                  | <2.35 days (n = 305) | >2.35 days (n = 305) | OR    | 95% CI       | Adj OR | 95% CI       | P value |
|------------------|----------------------|----------------------|-------|--------------|--------|--------------|---------|
| Gender           |                      |                      |       |              |        |              |         |
| Men              | 83 (27)              | 46 (15)              | 1.0   |              | 1.0    |              |         |
| Women            | 222 (73)             | 259 (85)             | 2.10  | 1.41–3.15    | 2.18   | 1.42–3.36    | <0.001  |
| Age (years)      |                      |                      |       |              |        |              |         |
| <30              | 74 (24)              | 67 (22)              | 1.0   |              | 1.0    |              |         |
| 30–39            | 79 (26)              | 62 (20)              | 0.33  | 0.10–1.07    | 0.82   | 0.49–1.37    | 0.42    |
| 40–49            | 52 (17)              | 49 (16)              | 0.36  | 0.09–1.35    | 0.88   | 0.50–1.54    | 0.65    |
| 50–59            | 57 (19)              | 57 (19)              | 0.63  | 0.20–1.93    | 0.90   | 0.51–1.57    | 0.70    |
| ≥60              | 43 (14)              | 70 (23)              | 1.94  | 0.66–5.67    | 1.35   | 0.75–2.43    | 0.31    |
| Smoking          |                      |                      |       |              |        |              |         |
| Non-smoker       | 212 (70)             | 191 (63)             | 1.36  | 0.97–1.90    | 1.42   | 0.97–2.08    | 0.07    |
| Smoker           | 93 (30)              | 114 (37)             |       |              |        |              |         |
| Coffee (cups/week)|                      |                      |       |              |        |              |         |
| 0–6              | 116 (38)             | 88 (29)              | 1.0   |              | 1.0    |              |         |
| 7–14             | 101 (33)             | 99 (32)              | 1.29  | 0.87–1.91    | 1.30   | 0.84–2.03    | 0.24    |
| 15–64            | 87 (28)              | 117 (38)             | 1.77  | 1.20–2.62    | 1.64   | 1.01–2.66    | 0.04    |
| Missing          | 1 (0.3)              | 1 (0.3)              |       |              |        |              |         |
| Tea (cups/week)  |                      |                      |       |              |        |              |         |
| 0                | 141 (46)             | 152 (50)             | 1.0   |              | 1.0    |              |         |
| 1–4              | 53 (17)              | 56 (18)              | 0.98  | 0.63–1.52    | 1.17   | 0.73–1.88    | 0.52    |
| 5–52             | 110 (36)             | 96 (32)              | 0.81  | 0.56–1.16    | 0.96   | 0.65–1.44    | 0.86    |
| Missing          | 1 (0.3)              | 1 (0.3)              |       |              |        |              |         |
| Alcohol (std/week)|                      |                      |       |              |        |              |         |
| 0                | 146 (48)             | 167 (55)             | 1.0   |              | 1.0    |              |         |
| 1–2              | 46 (15)              | 50 (16)              | 0.95  | 0.60–1.50    | 0.79   | 0.17–3.72    | 0.77    |
| 3–30             | 104 (34)             | 84 (28)              | 0.71  | 0.49–1.02    | 0.60   | 0.12–2.89    | 0.52    |
| Missing          | 9 (3)                | 4 (1)                |       |              |        |              |         |
| Alcohol          |                      |                      |       |              |        |              |         |
| No alcohol       | 148 (48)             | 168 (55)             | 1.0   |              | 1.0    |              |         |
| Spirits          | 14 (5)               | 13 (4)               | 0.82  | 0.37–1.77    | 1.02   | 0.18–5.87    | 0.98    |
| Wine             | 101 (33)             | 97 (32)              | 0.85  | 0.59–1.21    | 1.81   | 0.25–5.66    | 0.84    |
| Beer             | 33 (11)              | 23 (8)               | 0.61  | 0.34–1.09    | 0.90   | 0.18–4.60    | 0.90    |
| Missing          | 9 (3)                | 4 (1)                |       |              |        |              |         |
| Laxative         |                      |                      |       |              |        |              |         |
| No medicine      | 249 (81)             | 199 (65)             | 1.0   |              | 1.0    |              |         |
| Bulk-forming     | 28 (9)               | 48 (16)              | 2.14  | 1.30–3.54    | 2.10   | 1.23–3.59    | 0.007   |
| Osmotic          | 7 (2)                | 26 (9)               | 4.65  | 1.98–10.93   | 4.67   | 1.93–11.34   | 0.001   |
| Stool softener   | 7 (2)                | 13 (4)               | 2.32  | 0.91–5.93    | 2.26   | 0.86–5.95    | 0.10    |
| Stimulant        | 10 (3)               | 15 (5)               | 1.88  | 0.82–4.27    | 1.53   | 0.65–3.64    | 0.33    |
| Missing          | 4 (1)                | 4 (1)                |       |              |        |              |         |

Colonics transit time was divided into shorter and longer transit time by the median values. Values are presented as crude odds ratio (OR) and 95% confidence interval (CI). Adjusted ORs are adjusted for all variables.
P < 0.05 is considered statistically significant.
Std, standard drinks.

P = 0.001), and shorter CTT (2.1 [1.4–3.0] days vs. 2.5 [1.5–4.1] days, P <0.001), with a tendency to higher stool frequency (6.5 [5–10] vs. 6 [3–10], P = 0.08), compared to patients with any ongoing medication. Furthermore, prolonged CTT was less common in both men (29% vs. 49%, P = 0.04) and women (14% vs. 26%, P = 0.01) without any medication, compared to patients with motility-affecting medication.

Discussion

The main findings in the present study were that female sex, high coffee consumption, use of bulk-forming and osmotic laxatives, low stool frequency, shaped stool, and perception of constipation were associated with longer CTT. High coffee consumption and use of bulk-forming laxatives were associated with prolonged
CTT in men; use of osmotic and stimulant laxatives were associated with prolonged CTT in women. Patients who did not use motility-affecting drugs had shorter CTT, lower prevalence of prolonged CTT, and fewer GI symptoms than patients without such drugs.

The unexpected absence of association between CTT and age in the present study may depend on few included older individuals (>60 years) (12). In accordance with previous studies (6,7), women were found to have almost 50% longer CTT with 2.5 days versus 1.7 days for men; shaped stool form was positively associated with higher CTT and stool frequency was negatively associated with CTT. Furthermore, women’s weekly summarized abdominal pain was rated twice as high and their summarized perception of constipation was rated six times higher, compared to men. Abdominal pain may be explained by side effects from medical treatment or presence of organic diseases.

Table 3. Associations with pathologic colonic transit time in men and women.

|                  | Men                      | Women                     |
|------------------|--------------------------|----------------------------|
|                  | ≤2.2 days (n = 79)       | >2.2 days (n = 50) Adj OR 95% CI | ≤4.2 days (n = 376)       | >4.2 days (n = 105) Adj OR 95% CI |
| Age (years)      |                          |                            |                          |                                 |
| <30              | 15 (19)                  | 13 (26)                   | 1.0                      | 95 (25)                        | 18 (17)                   | 1.0                      |
| 30–39            | 24 (309)                 | 6 (12)                    | 0.28                     | 9 (24)                         | 20 (19)                   | 0.97                     | 0.45–2.10                |
| 40–49            | 14 (18)                  | 5 (10)                    | 0.24                     | 62 (16)                        | 20 (19)                   | 1.34                     | 0.61–2.96                |
| 50–59            | 16 (20)                  | 9 (18)                    | 0.50                     | 68 (18)                        | 21 (20)                   | 1.33                     | 0.60–2.94                |
| ≥60              | 10 (13)                  | 17 (34)                   | 0.91                     | 60 (16)                        | 26 (25)                   | 1.51                     | 0.69–3.29                |
| Smoking (n, %)   |                          |                            |                          |                                 |
| Non-smoker       | 54 (68)                  | 35 (70)                   |                          | 250 (66)                        | 64 (61)                   |                          |
| Smoker           | 25 (329)                 | 15 (30)                   |                          | 126 (34)                        | 41 (39)                   |                          |
| Coffee (cups/week) |                        |                            |                          |                                 |
| 0–6              | 31 (39)                  | 10 (20)                   | 1.0                      | 134 (36)                        | 29 (28)                   | 1.0                      |
| 7–14             | 28 (35)                  | 16 (32)                   | 1.63                     | 126 (34)                        | 30 (29)                   | 1.13                     | 0.60–2.12                |
| 15–64            | 20 (25)                  | 23 (46)                   | 4.67                     | 115 (31)                        | 46 (44)                   | 1.66                     | 0.88–3.13                |
| Missing          | 1 (2)                    | 1 (2)                     |                          | 1 (0.3)                         |                          |                          |
| Tea (cups/week)  |                          |                            |                          |                                 |
| 0                | 34 (43)                  | 30 (60)                   |                          | 170 (45)                        | 59 (56)                   | 1.0                      | 0.59–2.08                |
| 1–4              | 17 (22)                  | 5 (10)                    |                          | 67 (18)                         | 20 (19)                   | 1.11                     | 0.43–1.30                |
| 5–52             | 28 (35)                  | 15 (30)                   |                          | 137 (36)                        | 26 (25)                   | 0.74                     | 0.43–1.30                |
| Alcohol (std/week) |                        |                            |                          |                                 |
| 0                | 38 (48)                  | 33 (66)                   |                          | 179 (48)                        | 63 (60)                   | 1.0                      | 0.17–26.64               |
| 1–2              | 9 (11)                   | 3 (6)                     |                          | 68 (18)                         | 16 (15)                   | 0.56                     | 0.05–5.88                |
| Missing          | 2 (2)                    | 1 (2)                     |                          | 120 (32)                        | 25 (24)                   | 0.52                     | 0.05–5.63                |
| Alcohol (n, %)   |                          |                            |                          |                                 |
| No alcohol       | 39 (49)                  | 34 (68)                   |                          | 9 (2)                           | 1 (1)                     |                          |
| Spirits          | 5 (6)                    | 1 (2)                     |                          | 180 (48)                        | 63 (60)                   | 1.0                      | 0.17–26.64               |
| Wine             | 19 (24)                  | 9 (18)                    |                          | 14 (4)                          | 7 (7)                     | 2.12                     | 0.10–10.75               |
| Beer             | 14 (18)                  | 5 (10)                    |                          | 141 (38)                        | 29 (28)                   | 1.03                     | 0.10–10.75               |
| Missing          | 2 (2)                    | 1 (2)                     |                          | 32 (8)                          | 5 (5)                     | 0.89                     | 0.07–10.77               |
| Laxative (n, %)  |                          |                            |                          |                                 |
| No medicine      | 67 (85)                  | 28 (56)                   | 1.0                      | 9 (2)                           | 1 (1)                     |                          |
| Bulk-forming     | 5 (6)                    | 10 (20)                   | 6.16                     | 288 (77)                        | 65 (62)                   | 1.0                      | 0.61–2.43                |
| Osmotic          | 2 (2)                    | 5 (10)                    | 4.23                     | 47 (12)                         | 14 (13)                   | 1.21                     | 0.61–2.43                |
| Stool softener   | 5 (10)                   | –                         | –                        | 14 (4)                          | 12 (11)                   | 3.47                     | 1.46–8.26                |
| Stimulant        | 4 (5)                    | 1 (2)                     | 0.27                     | 12 (3)                          | 3 (3)                     | 1.00                     | 0.26–3.79                |
| Missing          | 1 (1)                    | 1 (2)                     |                          | 11 (3)                          | 9 (9)                     | 3.16                     | 1.20–8.30                |

Colonic transit time (CTT) > 2.2 days was defined as prolonged CTT in men and CTT > 4.2 days was defined as prolonged CTT in women (6,7). Values are presented as adjusted odds ratio (OR) and 95% confidence interval (CI). Adjusted for all variables with statistical significance in the unconditional regression.

P < 0.05 is considered statistically significant.

Std, standard drinks.
Peripheral or visceral hypersensitivity may be another explanation for abdominal pain (1,13–16). Differences in GI symptoms between sexes have been hypothesized to depend on involvement of ovarian hormones (17).

The current results suggest that constipation should be treated with laxatives and abdominal pain with pain-modulating agents, provided there was an absence of any organic GI disease demanding specific treatment. In addition, slow transit constipation and outlet obstruction are successfully treated with laxatives in many cases (12). From a clinical point of view, a transit time examination may be of limited importance for the treatment strategy. From a scientific point of view, it may be important to classify normal or delayed transit time and explore molecular mechanisms, to identify subgroups of patients with or without organic signs of gut dysmotility. However, an examination during influence of laxatives and other motility-affecting drugs may give unreliable information.

All patients were instructed to refrain from laxatives during the study period. Still, around 25% of the patients used different types of laxatives. Bulk-forming, osmotic, and stimulant laxatives were associated with prolonged transit time, although an improvement of transit time has been documented by these agents (18,19). The explanation to the associations may probably be that patients with longest transit times were in greatest need to be relieved of their symptoms.

### Table 4. Associations between symptoms and colonic transit time.

| Stool frequency | ≤7 (n = 113) | >7 (n = 113) | OR | 95% CI | Adj OR | 95% CI | P value |
|-----------------|-------------|-------------|----|--------|--------|--------|--------|
| **CTT (days)**  |             |             |    |        |        |        |        |
| ≤1.5            | 20 (18)     | 42 (37)     | 1.0| 1.0    | 1.0    | 1.0    |        |
| 1.6–2.35        | 29 (26)     | 42 (37)     | 0.69| 0.34–1.41| 0.69| 0.33–1.43| 0.32 |
| 2.36–3.6        | 34 (30)     | 21 (19)     | 0.29| 0.14–0.63| 0.38| 0.17–0.84| 0.02 |
| ≥3.7            | 30 (26)     | 8 (7)       | 0.13| 0.05–0.33| 0.16| 0.06–0.40| <0.001|

| Stool form      | Watery (n = 15) | Shaped (n = 87) | OR | 95% CI | Adj OR | 95% CI | P value |
|-----------------|----------------|----------------|----|--------|--------|--------|--------|
| **CTT (days)**  |             |             |    |        |        |        |        |
| ≤1.5            | 4 (21)       | 9 (10)       | 1.0| 1.0    | 1.0    | 1.0    |        |
| 1.6–2.35        | 6 (40)       | 28 (32)      | 2.07| 0.48–9.03| 2.74| 0.58–13.05| 0.21 |
| 2.36–3.6        | 4 (27)       | 27 (31)      | 3.00| 0.62–14.54| 3.71| 0.72–19.12| 0.12 |
| ≥3.7            | 1 (7)        | 23 (26)      | 10.22| 1.00–104.32| 13.35| 1.20–148.10| 0.04 |

| Perception of constipation | ≤1 (n = 113) | ≥1 (n = 113) | OR | 95% CI | Adj OR | 95% CI | P value |
|----------------------------|-------------|-------------|----|--------|--------|--------|--------|
| **CTT (days)**             |             |             |    |        |        |        |        |
| ≤1.5                       | 42 (37)     | 20 (18)     | 1.0| 1.0    | 1.0    | 1.0    |        |
| 1.6–2.35                   | 36 (32)     | 36 (32)     | 2.10| 1.04–4.25| 2.09| 1.03–4.25| 0.04 |
| 2.36–3.6                   | 21 (18)     | 33 (29)     | 3.30| 1.54–7.08| 2.98| 1.36–6.54| 0.007|
| ≥3.7                       | 15 (13)     | 24 (21)     | 3.36| 1.46–7.76| 3.12| 1.33–7.32| 0.009|

| Perception of abdominal pain | ≤3 N = 112 | >3 N = 116 | OR | 95% CI | Adj OR | 95% CI | P value |
|------------------------------|------------|------------|----|--------|--------|--------|--------|
| **CTT (days)**               |            |            |    |        |        |        |        |
| ≤1.5                         | 37 (33)    | 25 (22)    | 1.0| 1.0    | 1.0    | 1.0    |        |
| 1.6–2.35                     | 35 (31)    | 37 (32)    | 1.56| 0.79–3.11| 1.58| 0.78–3.21| 0.205|
| 2.36–3.6                     | 20 (18)    | 35 (30)    | 2.59| 1.23–5.47| 1.92| 0.88–4.21| 0.104|
| ≥3.7                         | 20 (18)    | 19 (16)    | 1.41| 0.63–3.15| 1.08| 0.47–2.50| 0.854|

The number of stools passing/week was divided into two groups by the median value of 7. Perception of constipation and abdominal pain were rated on a scale of 0–3 for each day and summarized to a total number in the range of 0–18, divided into two groups by the median value. Values are presented as crude odds ratio (OR) and 95% confidence interval (CI). Adjusted OR are adjusted for sex and smoking. P < 0.05 is considered statistically significant.

CTT, colonic transit time; n = number (%) of patients without laxatives and any motility-stimulating agents (n = 228).
The effect of coffee on GI transit time is insufficiently described. A recent study could not find any effect of coffee on gastric or small intestinal transit time (20), but older studies have shown that coffee stimulates colonic motility in healthy volunteers (21,22). Albeit no scientific evidence, there is a widespread conception in the general population that coffee induces defecation. In line with the higher consumption of certain laxatives among patients with the longer transit times, it is possible that the same patients tried to relieve their symptoms by extensive coffee consumption. In patients without any drug treatment, no association between coffee consumption and transit time was observed.

Alcohol intake did not show any overt effect on CTT, as described previously (23–25). The literature shows the minor importance of smoking and alcohol on functional bowel symptoms (26). In contrast, increased physical activity and dietary modification, which were not considered in the present study questionnaire, have been shown to be useful therapeutic tools in improvement of GI symptoms and colonic motility (27–30). The present results support the assumption that a pathologically prolonged CTT is caused by myopathic and/or neurologic abnormalities, refractory to several lifestyle interventions (12).

Many of the patients used drugs which may exert motility-reducing properties, such as opioids, beta blockers, antihypertensive drugs, and antidepressant medication, that could hypothetically explain the higher prevalence of prolonged CTT in the medication group. The need of this medical treatment should be re-evaluated considering their impact on GI transit time and symptoms, and the classification of normal or prolonged transit time may be misleading during this type of drug treatment.

The strength of the present study is the large cohort of consecutively examined individuals, along with completion of questionnaires concerning medication, lifestyle habits, and GI symptoms. However, there are several limitations in the study. The self-reporting questionnaire allows the participant to under- or overestimate their consumption or symptoms. Diet and fluid intake as well as the grade of physical activity were not considered. The phase of the menstrual cycle was unknown. Moreover, we did not know the diagnoses of the patients referred for CTT. Since the majority of patients who seek help for constipation and abdominal pain are diagnosed as FGID, one can speculate that the majority of the examined participants suffered from this disorder, but the possibility exists that patients with diseases such as diabetes mellitus and neurologic disorders were included (12). Since the answer from the examinations were given in number of markers, without any description of the markers situated, regional transit time could not be estimated. Thus, from the reply given to the clinician, it was impossible to differ between colonic inertia and outlet obstruction in the cases of prolonged CTT. A shorter examination period could be preferred to make it easier for the patients to refrain from drug treatments during the procedure (31). We could not assess short CTT, since the number of remaining rods were not given in several replies from the X-ray examination, and no questions about diarrhea were present in the diary.

In conclusion, the link between CTT and the aforementioned lifestyle factors is complex. Infrequent stool passing and perception of constipation may indicate prolonged transit time. Transit time examination may be redundant to handle patients with mainly symptoms of abdominal pain. GI symptoms may be secondary side effects to several drugs, which should be considered when actual, and drugs should be withdrawn before examination of CTT.

Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was financed by grants from the Development Foundation of Region Skane.

ORCID iD
Bodil Ohlsson http://orcid.org/0000-0002-9142-5244

References
1. Lacy BE, Mearin F, Chang L, et al. Bowel disorders. Gastroenterology 2016;150:1393–1407.
2. Levenstein S, Prantera C. Psychological factors, symptoms, and mucosal inflammation in inflammatory bowel disease. Am J Gastroenterol 2016;111:1498–1499
3. Shakil A, Church RJ, Rao SS. Gastrointestinal complications of diabetes. Am Fam Physician 2008;77:1697–1702.
4. Alkhawajah MM, Caminero AB, Freeman HJ, et al. Multiple sclerosis and inflammatory bowel diseases: what we know and what we would need to know! Mult Scler 2013;19:259–265.
5. Fasano A, Visanji NP, Liu LW, et al. Gastrointestinal dysfunction in Parkinson’s disease. Lancet Neurol 2015;14:625–639.
6. Sadik R, Abrahamsson H, Stotzer PO. Gender differences in gut transit shown with a newly developed radiological procedure. Scand J Gastroenterol 2003;38:36–42.
7. Tornblom H, Van Oudenhove L, Sadik R, et al. Colonic transit time and IBS symptoms: what’s the link? Am J Gastroenterol 2012;107:754–760.
8. Gronlund D, Poulsen JL, Sandberg TH, et al. Established and emerging methods for assessment of small and large intestinal motility. *Neurogastroenterol Motil* 2017;29. Doi: 10.1111/nmo.13008.

9. Available at: https://www.lupop.lu.se/lupop-for-allmanheten/pagaende-undersokningar.

10. Abrahamsson H, Antov S, Bosaeus I. Gastrointestinal and colonic segmental transit time evaluated by a single abdominal x-ray in healthy subjects and constipated patients. *Scand J Gastroenterol Suppl* 1988;152:72–80.

11. Ohlsson B. Läkemedelsboken: Tarmkanalens Funktionsrubbningar [updated 2017-11-16 10:16]. Available from: https://lakemedelsboken.se/kapitel/mage-tarm/tarmkanalens_funktionsrubbningar.html#Medel-mot-forstoppning

12. Forootan M, Bagheri N, Darvishi M. Chronic constipation: A review of literature. *Medicine* 2018;97:e10631.

13. Ossipov MH, Morimua K, Porreca F. Descending pain modulation and chronification of pain. *Curr Opin Support Palliat Care* 2014;8:143–151.

14. Bielefeldt K, Lamb K, Gebhart GF. Convergence of sensory pathways in the development of somatic and visceral hypersensitivity. *Am J Physiol Gastrointestinal Liver Physiol* 2006;291:G658–G665.

15. Latremoliere A, Woolf CJ. Central sensitization: A generator of pain hypersensitivity by central neural plasticity. *J Pain* 2009;10:895–926.

16. Elenbrouch S. How positive and negative expectations shape the experience of visceral pain. *Handb Exp Pharmacol* 2014;225:97–119.

17. Heitkemper MM, Chang L. Do fluctuations in ovarian hormones affect gastrointestinal symptoms in women with irritable bowel syndrome? *Gend Med* 2009;6:152–167.

18. Ewe K, Ueberschaer B, Press AG. Influence of senna, fibre, and fibre + senna on colonic transit in loperamide-induced constipation. *Pharmacology* 1999;47(Suppl. 1):242–248.

19. Fritz E, Hammer HF, Lipp RW, et al. Effects of lactulose and polyethylene glycol on colonic transit. *Aliment Pharmacol Ther* 2005;21:259–268.

20. Boekema PJ, Lo B, Samsom M, et al. The effect of coffee on gastric emptying and oro-caecal transit time. *Eur J Clin Invest* 2000;30:129–134.

21. Brown SR, Cann PA, Read NW. Effect of coffee on distal colon function. *Gut* 1990;31:450–453.

22. Rao SSC, Welcher K, Zimmerman B, et al. Is coffee a colonic stimulant? *Eur J Gastroenterol Hepatol* 1998;10:113–118.

23. Talley NJ, Zinsmeister AR, Melton LJ, 3rd. Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization. *Am J Epidemiol* 1995;142:76–83.

24. Nam SY, Kim BC, Ryu KH, et al. Prevalence and risk factors of irritable bowel syndrome in healthy screenee undergoing colonoscopy and laboratory tests. *J Neurogastroenterol Motil* 2010;16:47–51.

25. Chang FY, Chen PH, Wu TC, et al. Prevalence of functional gastrointestinal disorders in Taiwan: questionnaire-based survey for adults based on the Rome III criteria. *Asia Pac J Clin Nutr* 2012;21:594–600.

26. Ohlsson B (2017) The role of smoking and alcohol behaviour in management of functional gastrointestinal disorders. *Best Pract Res Clin Gastroenterol* 31:545–552.

27. Kang SH, Choi SW, Lee SJ, et al. The effects of lifestyle modification on symptoms and quality of life in patients with irritable bowel syndrome: a prospective observational study. *Gut Liver* 2011;5:472–477.

28. Kim YS, Song BK, Oh JS, et al. Aerobic exercise improves gastrointestinal motility in psychiatric inpatients. *World J Gastroenterol* 2014;20:10577–10584.

29. Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. *JAMA* 2015;313:949–958.

30. Ohlsson B, Manjer J (2016) Physical inactivity during leisure time and irregular meals are associated with functional gastrointestinal complaints in middle-aged and elderly subjects. *Scand J Gastroenterol* 51:1299–1307.

31. Alame AM, Bahna H. Evaluation of constipation. *Clin Colon Rectal Surg* 2012;25:5–11.